Laurus Labs Ltd Share Price
As on 21 November 2025 at 00:27 IST
Laurus Labs Ltd. Q1 FY26 Results:
Net profit for the period surged a staggering 1,154% to ₹163 crores in Q1 FY26, from ₹13 crores in Q1 FY25. Total income for the quarter increased 32% year-on-year to ₹1,580 crores, from ₹1,197 crores.
About Laurus Labs Ltd
Laurus Labs Ltd. is a leading research-driven pharmaceutical and biotechnology company. It was founded in the year 2005 by Dr. Satyanarayana Chava. The company has grown to become a significant player in the global pharmaceutical industry. The headquarters of the company is located in Hyderabad, Telangana. Laurus Lab's main products include active pharmaceutical ingredients (APIs), generic formulations, and speciality ingredients. The company also offers contract development and manufacturing organization (CDMO) services. Laurus Labs falls under the pharmaceutical and biotechnology sector. It has a strong market presence in the pharmaceutical industry. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
7.26%
Over 6 Months
62.59%
Over 1 Year
101.94%
Over 3 Years
117.20%
Laurus Labs Ltd Summary
Close ₹987.50
Open ₹1,010
High ₹1,010
Low ₹982.15
Volume 12,88,996
Net Turnover (in Cr) ₹127.54
52Wk High ₹1,033.50
52Wk Low ₹482.60
52Wk High / Low
482.60
1,033.50
Laurus Labs Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹53,307.71
EPS (TTM) 12.65
Book Value (BV) 91.11
Div. Yield 0.12 %
P/E (TTM) 78.06
Price/Book Value 10.84
Delivery % 43.26 %
Face Value 2
Key Ratios
PE Ratio 87.06
PB Ratio 7.25
EV to Sales 6.79
PEG Ratio 1.25
ROA 5.21
ROE 7.75
Debt-Equity 0.51
Net Profit Margin 6.52
Operating Profit Margin 18.91
Laurus Labs Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 5,629.06 | 5,067.17 | 6,046.55 | 4,950.87 | 4,837.17 |
| Total Expenses | 5,144.77 | 4,830.81 | 4,937.61 | 3,867.02 | 3,536.06 |
| Profit Before Tax | 484.29 | 236.36 | 1,108.94 | 1,083.85 | 1,301.11 |
| Profit After Tax | 354.41 | 168.21 | 796.64 | 832.43 | 983.82 |
| Operating Profit After Depreciation | 700.29 | 419.26 | 1,274.11 | 1,186.24 | 1,369.27 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 4,123.22 | 3,890.01 | 3,408.62 | 2,652.47 | 2,170.62 |
| Total Non Current Assets | 5,003.25 | 4,552.06 | 4,198.72 | 3,623.43 | 2,675.83 |
| Total Current Assets | 4,332.32 | 3,834.97 | 3,461.68 | 3,344.61 | 3,074.86 |
| Total Assets | 9,335.57 | 8,387.03 | 7,660.40 | 6,968.04 | 5,750.69 |
| Total Shareholder's Fund | 4,472.56 | 4,110.95 | 4,037.53 | 3,351.19 | 2,597.55 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 601.65 | 665.69 | 993.90 | 911.10 | 733 |
| Net Cash Used In Investing Activities | -680.33 | -822.25 | -996.94 | -914.47 | -940.93 |
| Net Cash Used In Financing Activities | 39.28 | 249.83 | -26.64 | 30.26 | 254.70 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 5,317.45 | 4,859.81 | 5,789.40 | 4,728.59 | 4,796.04 |
| Total Expenses | 4,813.64 | 4,558.34 | 4,737.97 | 3,753.18 | 3,521.41 |
| Profit Before Tax | 503.81 | 301.47 | 1,051.43 | 975.41 | 1,274.63 |
| Profit After Tax | 380.39 | 223.70 | 760.38 | 750.09 | 956.11 |
| Operating Profit After Depreciation | 686.01 | 452.29 | 1,197.13 | 1,071.27 | 1,340.55 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 2,887.50 | 3,036.31 | 2,884.16 | 2,186.23 | 1,818.04 |
| Total Non Current Assets | 4,579.97 | 4,150.37 | 3,786.70 | 3,403.96 | 2,583.74 |
| Total Current Assets | 4,006.78 | 3,517.11 | 3,171.26 | 3,204.57 | 3,041.45 |
| Total Assets | 8,586.75 | 7,667.48 | 6,957.96 | 6,608.53 | 5,625.19 |
| Total Shareholder's Fund | 4,563.95 | 4,207.05 | 4,056.82 | 3,388.21 | 2,712.24 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 540.06 | 658.54 | 881.55 | 822.97 | 694.45 |
| Net Cash Used In Investing Activities | -591.65 | -756.74 | -735.27 | -836.61 | -899.68 |
| Net Cash Used In Financing Activities | 59.32 | 139.41 | -185.19 | 15.19 | 243.13 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 1,653.47 | 1,569.57 | 1,720.30 | 1,415.05 | 1,223.70 |
| Total Expenses | 1,250.21 | 1,187.44 | 1,299.70 | 1,129.90 | 1,045.37 |
| Profit Before Tax | 269.73 | 224.22 | 312.34 | 130.68 | 22.81 |
| Profit After Tax | 193.75 | 161.08 | 233.87 | 90.61 | 17.72 |
| Operating Profit after Depreciation | 430.22 | 392.56 | 479.17 | 294.57 | 182.93 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 1,566.60 | 1,432.75 | 1,650.01 | 1,265.19 | 1,184.85 |
| Total Expenses | 1,176.94 | 1,105.37 | 1,255.18 | 1,058.91 | 1,003.02 |
| Profit Before Tax | 288.84 | 211.44 | 330.20 | 76.72 | 58.09 |
| Profit After Tax | 215.67 | 157.94 | 251.90 | 57.27 | 42.44 |
| Operating Profit after Depreciation | 418.11 | 348.90 | 466.99 | 213.40 | 193.72 |
Laurus Labs Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 976.43
S2 965.37
S3 948.58
Pivot 993.22
R1 1,004.28
R2 1,021.07
R3 1,032.13
Moving Average
20 SMA 973.95
50 SMA 920.37
100 SMA 875.76
200 SMA 740.48
Laurus Labs Ltd Corporate Actions
Laurus Labs Ltd
₹0.8/Share
Announcement Date 31 Oct 2025
Record Date 31 Oct 2025
Div Yield 40%
Laurus Labs Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,784.15 | ₹4,28,077.35 |
| Divis Laboratories Ltd | ₹6,453.65 | ₹1,71,324.13 |
| Torrent Pharmaceuticals Ltd | ₹3,729.85 | ₹1,26,229.40 |
| Cipla Ltd | ₹1,526.35 | ₹1,23,294.16 |
| Dr Reddys Laboratories Ltd | ₹1,250.10 | ₹1,04,335.99 |
Laurus Labs Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| DSP Healthcare Fund | 6.73% |
| SBI Healthcare Opportunities Fund | 3.27% |
| Mahindra Manulife Multi Cap Fund | 2.33% |
| Mirae Asset ELSS Tax Saver Fund | 1.77% |
| Mirae Asset Midcap Fund | 1.62% |
Laurus Labs Ltd News
Laurus Labs gains after reporting multi-fold jump in Q2 PAT to Rs 195 cr
Laurus Labs advanced 1.60% to Rs 938.60 after the company's consolidated net profit soared 882.71% to Rs 194.97 crore on 35.12% increase in revenue from operations to Rs 1653.47 crore in Q2 FY26 over Q2 FY25.
23 Oct 2025, 04:30 pm
Board of Laurus Labs recommends interim dividend
Of Rs 0.8 per share
23 Oct 2025, 03:33 pm
Laurus Labs to table results
On 23 October 2025
10 Oct 2025, 10:15 am
Laurus Labs Ltd gains for third straight session
Laurus Labs Ltd is quoting at Rs 862.05, up 2.41% on the day as on 12:49 IST on the NSE. The stock is up 87.08% in last one year as compared to a 1.89% slide in NIFTY and a 6.42% slide in the Nifty Pharma index.
01 Oct 2025, 01:05 pm
Laurus Labs Ltd soars 1.7%
Laurus Labs Ltd is quoting at Rs 874.75, up 1.7% on the day as on 12:49 IST on the NSE. The stock is up 83.93% in last one year as compared to a 2.31% drop in NIFTY and a 5.43% drop in the Nifty Pharma index.
03 Sep 2025, 01:05 pm
Laurus Labs Ltd Stock Analysis
- Annual revenue for Laurus Labs Ltd increased by 9.42% to ₹5,317.45 crore in FY 2025 from ₹4,859.81 crore in FY 2024.
- Annual Net Profit for Laurus Labs Ltd increased by 70.04% to ₹380.39 crore in FY 2025 from ₹223.70 crore in FY 2024.
- Promoter Shareholding in Laurus Labs Ltd remains unchanged by 0.00% in the most recent quarter, from 27.59% in June 2025 to 27.59% in September 2025.
- Laurus Labs Ltd delivered a 1-year return of 101.94% compared to the Nifty 50, which provided a return of 10.78% as of the last trading session.
- Laurus Labs Ltd share price moved down by 0.50% from its previous close of INR ₹987.50. The latest Laurus Labs Ltd share price is INR ₹982.55.
- Laurus Labs Ltd share price today has been at a low of 970.25 and a high of 991.10. Over the past 52 weeks, the Laurus Labs Ltd share price has seen a low of 482.60 and a high of 1,033.50.
About Laurus Labs Ltd
Laurus Labs Ltd. is a top research-driven pharmaceutical and biotechnology company. The company focuses on the development, manufacture, and sale of active pharmaceutical ingredients (APIs), generic formulations, and speciality ingredients. Laurus Labs also provides contract development and manufacturing organization (CDMO) services. It is catering to both generic and proprietary pharmaceutical markets.
Laurus Labs falls under the pharmaceutical and biotechnology sector. The company was established in 2005 by Dr. Satyanarayana Chava. Since its inception, Laurus Labs has grown to become a significant player in the global pharmaceutical industry. The company is known for its innovation and quality.
The headquarters of Laurus Labs Ltd. is located in Hyderabad, Telangana, India. The company is promoted by Dr. Satyanarayana Chava, who has been instrumental in driving the company's growth and success. He also serves as the CEO and Executive Director of the company. The crucial managerial promoters of the company include:
Laurus Labs is one of the largest suppliers of antiretroviral APIs globally. The company's robust capabilities and global reach have positioned it as a key player in the sector. The promoter shareholding in Laurus Labs Ltd. stands at 27.28%. The M/s. NSN Holdings owns a major stake (23.02%) among the total promoter shareholdings. This indicates strong promoter commitment to the business.
The registered office of Laurus Labs Ltd. is located at Vishakapatnam, Andhra Pradesh, 531021, India. Its registrar & transfer agent is KFin Technologies Private Limited.
Laurus Labs Ltd. is a well-established pharmaceutical and biotechnology company in India. The company is known for its comprehensive range of products and strong market presence.
Global Presence Laurus Labs has established a strong international presence. Its operations span across multiple continents, including North America, Europe, Asia, and Africa. The company's extensive global footprint is a testament to its ability to deliver high-quality pharmaceutical products and services to clients worldwide. Laurus Labs' international base is supported by its strategically located offices, manufacturing facilities, and research and development centres around the world.
Key International Markets Laurus Labs has successfully penetrated key international markets. This includes the United States, Europe, and emerging markets in Asia and Africa. In the United States, the company has a strong presence in the generic formulations market. This is because it supplies a wide range of products to major pharmaceutical companies. Laurus Lab's products are also well-received in Europe. In this country, the company has established long-term partnerships with leading pharmaceutical firms. The company's presence in emerging markets, such as India, China, and South Africa, has further strengthened its global reach and market position.
Manufacturing Capabilities Laurus Labs' international base is further strengthened by its state-of-the-art manufacturing facilities. The company operates many manufacturing plants in India. These are equipped with advanced technology and adhere to stringent quality standards. These facilities are approved by major regulatory authorities, including the US FDA, WHO, and EMA. This ensures the production of high-quality pharmaceutical products that meet global requirements. Laurus Labs' manufacturing capabilities enable it to cater to the diverse needs of its international clients and maintain a competitive edge in the global market.
Research and Development Laurus Labs places a strong emphasis on research and development (R&D). This aids in driving innovation and maintaining its leadership position in the pharmaceutical industry. The company operates multiple R&D centres in India. At this centre, it focuses on developing new and advanced pharmaceutical products. Laurus Labs' R&D efforts are supported by a team of highly skilled scientists and researchers. They work on cutting-edge technologies and methodologies. The company's commitment to R&D has resulted in a robust pipeline of products that cater to the evolving needs of its global clients.
Strategic Partnerships and Alliances Laurus Labs has established strategic partnerships. Also, its alliances with leading global pharmaceutical companies enhance its international operations. These collaborations enable the company to leverage local expertise, access new markets, and deliver innovative solutions to its clients. Laurus Labs has strengthened its position as a trusted global pharmaceutical partner. This is achieved by forming alliances with reputable international firms.
Laurus Labs Ltd. has established a strong international base. It has a presence on multiple continents and a track record of successfully delivering high-quality pharmaceutical products and services worldwide. The company's commitment to innovation, quality, and customer satisfaction has solidified its position as a leading globally. It remains dedicated to delivering world-class pharmaceutical solutions that drive global health and well-being as the company continues to expand its international footprint.
Laurus Labs falls under the pharmaceutical and biotechnology sector. The company was established in 2005 by Dr. Satyanarayana Chava. Since its inception, Laurus Labs has grown to become a significant player in the global pharmaceutical industry. The company is known for its innovation and quality.
The headquarters of Laurus Labs Ltd. is located in Hyderabad, Telangana, India. The company is promoted by Dr. Satyanarayana Chava, who has been instrumental in driving the company's growth and success. He also serves as the CEO and Executive Director of the company. The crucial managerial promoters of the company include:
- Ravindranath Kancherla
- V V Ravi Kumar
- C V Lakshmana Rao
- Krishna Chaitanya Chava
Laurus Labs is one of the largest suppliers of antiretroviral APIs globally. The company's robust capabilities and global reach have positioned it as a key player in the sector. The promoter shareholding in Laurus Labs Ltd. stands at 27.28%. The M/s. NSN Holdings owns a major stake (23.02%) among the total promoter shareholdings. This indicates strong promoter commitment to the business.
The registered office of Laurus Labs Ltd. is located at Vishakapatnam, Andhra Pradesh, 531021, India. Its registrar & transfer agent is KFin Technologies Private Limited.
Laurus Labs Ltd. is a well-established pharmaceutical and biotechnology company in India. The company is known for its comprehensive range of products and strong market presence.
International Base of the Company
Laurus Labs Ltd. is a research-driven pharmaceutical and biotechnology leader. It specializes in active pharmaceutical ingredients (APIs), generic formulations, and specialty ingredients manufacturing. The company combines its development expertise with CDMO services, serving both generic and proprietary pharmaceutical markets through its comprehensive development and manufacturing capabilities.Global Presence Laurus Labs has established a strong international presence. Its operations span across multiple continents, including North America, Europe, Asia, and Africa. The company's extensive global footprint is a testament to its ability to deliver high-quality pharmaceutical products and services to clients worldwide. Laurus Labs' international base is supported by its strategically located offices, manufacturing facilities, and research and development centres around the world.
Key International Markets Laurus Labs has successfully penetrated key international markets. This includes the United States, Europe, and emerging markets in Asia and Africa. In the United States, the company has a strong presence in the generic formulations market. This is because it supplies a wide range of products to major pharmaceutical companies. Laurus Lab's products are also well-received in Europe. In this country, the company has established long-term partnerships with leading pharmaceutical firms. The company's presence in emerging markets, such as India, China, and South Africa, has further strengthened its global reach and market position.
Manufacturing Capabilities Laurus Labs' international base is further strengthened by its state-of-the-art manufacturing facilities. The company operates many manufacturing plants in India. These are equipped with advanced technology and adhere to stringent quality standards. These facilities are approved by major regulatory authorities, including the US FDA, WHO, and EMA. This ensures the production of high-quality pharmaceutical products that meet global requirements. Laurus Labs' manufacturing capabilities enable it to cater to the diverse needs of its international clients and maintain a competitive edge in the global market.
Research and Development Laurus Labs places a strong emphasis on research and development (R&D). This aids in driving innovation and maintaining its leadership position in the pharmaceutical industry. The company operates multiple R&D centres in India. At this centre, it focuses on developing new and advanced pharmaceutical products. Laurus Labs' R&D efforts are supported by a team of highly skilled scientists and researchers. They work on cutting-edge technologies and methodologies. The company's commitment to R&D has resulted in a robust pipeline of products that cater to the evolving needs of its global clients.
Strategic Partnerships and Alliances Laurus Labs has established strategic partnerships. Also, its alliances with leading global pharmaceutical companies enhance its international operations. These collaborations enable the company to leverage local expertise, access new markets, and deliver innovative solutions to its clients. Laurus Labs has strengthened its position as a trusted global pharmaceutical partner. This is achieved by forming alliances with reputable international firms.
Laurus Labs Ltd. has established a strong international base. It has a presence on multiple continents and a track record of successfully delivering high-quality pharmaceutical products and services worldwide. The company's commitment to innovation, quality, and customer satisfaction has solidified its position as a leading globally. It remains dedicated to delivering world-class pharmaceutical solutions that drive global health and well-being as the company continues to expand its international footprint.
FAQ’s
What is the share price of Laurus Labs Ltd today?
Laurus Labs Ltd share price as on 20 Nov 2025 is ₹ 982.55
What is the Market Cap of Laurus Labs Ltd?
The market cap of Laurus Labs Ltd stock is ₹53,307.71 Cr.
What is the PE Ratio of Laurus Labs Ltd?
The Price to Earnings (P/E) Ratio of Laurus Labs Ltd is 87.06
What is the PB Ratio of Laurus Labs Ltd?
The Price to Book (P/B) Ratio of Laurus Labs Ltd is 7.25
What is the 52 week high of Laurus Labs Ltd Share Price?
The 52 week high of Laurus Labs Ltd share price stands at ₹1,033.50
What is the 52 week low of Laurus Labs Ltd Share Price?
The 52 week low of Laurus Labs Ltd share price stands at ₹482.60
How can I buy shares of Laurus Labs Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Laurus Labs Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
